Lite Strategy, Inc. (LITS)
1.04
+0.05
(+5.08%)
USD |
NASDAQ |
Aug 24, 16:00
1.07
+0.03
(+2.88%)
After-Hours: 20:00
Lite Strategy EPS Diluted (Quarterly) : -0.6635 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -0.6635 |
| December 31, 2025 | -0.8241 |
| September 30, 2025 | -0.1235 |
| June 30, 2025 | -0.4034 |
| March 31, 2025 | -0.3862 |
| December 31, 2024 | -0.4018 |
| September 30, 2024 | -1.202 |
| June 30, 2024 | -2.762 |
| March 31, 2024 | -1.370 |
| December 31, 2023 | -1.660 |
| September 30, 2023 | 8.461 |
| June 30, 2023 | -1.505 |
| March 31, 2023 | -2.317 |
| December 31, 2022 | 1.539 |
| September 30, 2022 | -2.495 |
| June 30, 2022 | -2.413 |
| March 31, 2022 | -1.311 |
| December 31, 2021 | -2.749 |
| September 30, 2021 | -3.528 |
| June 30, 2021 | -2.662 |
| March 31, 2021 | -4.553 |
| December 31, 2020 | -2.64 |
| September 30, 2020 | -2.665 |
| June 30, 2020 | -3.40 |
| March 31, 2020 | -0.8168 |
| Date | Value |
|---|---|
| December 31, 2019 | -5.146 |
| September 30, 2019 | -0.8132 |
| June 30, 2019 | -3.00 |
| March 31, 2019 | -4.875 |
| December 31, 2018 | -3.086 |
| September 30, 2018 | -4.103 |
| June 30, 2018 | -7.20 |
| March 31, 2018 | -3.20 |
| December 31, 2017 | -3.20 |
| September 30, 2017 | -4.80 |
| June 30, 2017 | -2.40 |
| March 31, 2017 | -0.40 |
| December 31, 2016 | 6.40 |
| September 30, 2016 | -2.40 |
| June 30, 2016 | -3.40 |
| March 31, 2016 | -3.20 |
| December 31, 2015 | -3.00 |
| September 30, 2015 | -2.60 |
| June 30, 2015 | -3.40 |
| March 31, 2015 | -5.40 |
| December 31, 2014 | -7.80 |
| September 30, 2014 | -8.40 |
| June 30, 2014 | -8.00 |
| March 31, 2014 | -6.80 |
| December 31, 2013 | -6.40 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | -0.0508 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -23.69M |
| Total Expenses (Quarterly) | 23.69M |
| Enterprise Value | 27.25M |
| Earnings Yield | -193.7% |
| Normalized Earnings Yield | -102.94 |